Scheithauer W, Funovics J, Mueller C, Ludwig H
Department of Gastroenterology II, University Medical School, Vienna, Austria.
J Cancer Res Clin Oncol. 1990;116(2):132-3. doi: 10.1007/BF01612666.
A phase II trial of sequential high-dose methotrexate, 1500 mg/m2, and 5-fluorouracil, 1500 mg/m2 intravenously on day 1, plus doxorubicin, 30 mg/m2 i.v. on day 14, has been undertaken in patients with locally advanced or metastatic adenocarcinoma of the pancreas. Of 25 evaluable patients there were 1 complete response and 3 partial responses for an overall response rate of 16% (95% confidence interval 5%-36%). The median survival of all patients was 6.7 months (range 1-17 months). There was one treatment-related death due to pancytopenia and sepsis. In all other patients therapy was generally well-tolerated. We conclude that this combination protocol has only modest activity in the treatment of advanced pancreatic cancer.
一项针对局部晚期或转移性胰腺腺癌患者的II期试验采用了序贯大剂量甲氨蝶呤（1500 mg/m²）和5-氟尿嘧啶（第1天静脉注射1500 mg/m²），外加阿霉素（第14天静脉注射30 mg/m²）。25例可评估患者中，有1例完全缓解，3例部分缓解，总缓解率为16%（95%置信区间5%-36%）。所有患者的中位生存期为6.7个月（范围1-17个月）。有1例因全血细胞减少和败血症导致的治疗相关死亡。在所有其他患者中，治疗一般耐受性良好。我们得出结论，该联合方案在晚期胰腺癌治疗中仅具有适度活性。
